New China Life Insurance Updates Board and Committees
New China Life Insurance Updates Board Committee Members
GTJA: It is expected that life insurance will shift to a strong performance in 2025 while property insurance will grow steadily.
The negative month-on-month premium growth in the life insurance sector for November does not change the annual growth expectations, health insurance is recovering while accident insurance remains under pressure; the recovery in new car sales is driving an improvement in auto insurance growth, while non-auto insurance continues to grow to achieve annual targets.
New China Life Insurance (01336) elected Gong Xingfeng as a member of the Board of Directors' Global Strategy Committee.
New China Life Insurance (01336) announced that on December 27, 2024, the 28th meeting of the 8th Board of Directors...
Guolian: Stricter regulations in 2025 are expected to encourage leading insurance companies to expand their advantages.
With the implementation of the "reporting and operating as one" policy in the individual insurance channel, the continued decrease in product reservation rates, and the active adjustment of product structure by insurance companies, the NBV Margin is expected to further improve by 2025, thereby supporting the positive growth of NBV.
New China Life Insurance Unveils Board Structure
New China Life Insurance (01336.HK: Gong Xingfeng's qualifications to serve as Director, President, and Chief Financial Officer of the company have been approved.
On December 24, Gelonghui reported that New China Life Insurance (01336.HK) announced that it recently received the National Financial Supervisory Administration's ("Financial Regulatory Authority") approvals regarding the qualification of Gong Xingfeng as a Director of New China Life Insurance Co., Ltd. (No. Jin Fu [2024] 819), the approval of Gong Xingfeng as General Manager (No. Jin Fu [2024] 843), and the approval of Gong Xingfeng as Financial Officer (No. Jin Fu [2024] 825), and the Financial Regulatory Authority has approved Gong Xingfeng.
Rescue or 'bottom fishing'? Four insurance companies have acquired 15 Wanda Assets this year.
New China Life Insurance (601336.SH) has taken over another Wanda Assets. According to Tianyancha information, Wanda Plazas in Chifeng and Jinjiang have already occurred...
After long-term bonds fell below 2%, insurance funds shifted towards equity assets, with high dividend and high ROE being the top choices.
Recently, the yield on 30-year government bonds has fallen below 2.0%. Guosen believes that the central tendency of long-term bond rates continues to decline, and the pressure on investment income from insurance funds is further increasing. Since the beginning of this year, companies represented by Great Wall Life, China Pacific Insurance, and Ruizhong Life have been increasing their stakes in high-quality listed companies, mainly concentrated in industries such as utilities, transportation, and Banks, which have high dividend yields and relatively stable ROE levels.
A Closer Look At New China Life Insurance Company Ltd.'s (SHSE:601336) Impressive ROE
Three insurance companies have been approved to issue bonds worth 39 billion. Insurance companies have replenished a total of 117.5 billion yuan this year, slightly exceeding last year's total.
① On the same day, the Financial Regulatory Bureau disclosed that the perpetual bonds or capital supplement bonds issued by Ping An Life, China Postal Insurance, and China United Property Insurance have been approved, with a cumulative approved issuance scale not exceeding 39 billion yuan; ② The demand for "blood replenishment" in the Insurance Industry remains significant within the year. As of December 20, the cumulative issuance scale of capital supplement bonds and perpetual bonds by Insurance Institutions has reached 117.5 billion yuan, slightly higher than the total for last year.
New China Life to Elect Directors at 2025 Meeting
Hong Kong stocks moved significantly | Mainland Insurance Companies rose in the afternoon as the booming auto sales drive high growth in auto insurance. Institutions indicate that auto insurance premiums are expected to further open up incremental space.
Mainland Insurance Companies rose in the afternoon. As of the time of writing, China Pacific Insurance (02601) is up 3.38%, priced at 24.45 HKD; CHINA TAIPING (00966) rose 2.06%, priced at 11.9 HKD; New China Life Insurance (01336) increased by 1.28%, priced at 23.8 HKD; China Life Insurance (02628) rose 1.24%, priced at 14.74 HKD.
Open-source securities: The proportion of dividend-type products has increased, and the strong start for insurance companies is expected to continue.
The transformation of individual insurance channels has shown results, and the medium to long-term demand for dividend insurance is promising; high-quality growth is expected to continue in 2025.
December 17 Insurance Daily | The premium income of listed insurance companies increased by 5.6% year-on-year in the first 11 months, and the "Retirement Finance" development roadmap has arrived!
In the first 11 months, listed insurance companies achieved a premium income of 2,666.7 billion yuan, a year-on-year increase of 5.6%. Some customer demand being overdrawn poses challenges for the "good start". Among the five A-share listed insurance companies, Ping An Insurance achieved a premium income of 796.396 billion yuan, a year-on-year increase of 7.9%; The People's Insurance achieved a premium income of 646.933 billion yuan, a year-on-year increase of 5.5%; China Life Insurance achieved a premium income of 644.3 billion yuan, a year-on-year increase of 4.8%; China Pacific Insurance achieved a premium income of 415.875 billion yuan, a year-on-year increase of 4.3%; New China Life Insurance achieved a premium income of
Passenger Vehicle Usage-based Insurance Market - Growth Opportunities Analysis 2024-2030
Guosen: Deposit rate cuts combined with product optimization drive a new round of "good start" for insurance companies.
The Insurance Industry's "New Year Start" in 2025 will focus on late November and early December, and it is expected that during this "New Year Start" period, the incremental opportunities may be concentrated in the exploration of increased insurance demand brought about by the combined product strategy.
[Brokerage Focus] Everbright points out that the growth rate of life insurance premiums is recovering and pays attention to the progress of the "New Year Opening" in 2025.
Jinwu Financial News | Everbright stated that recently, five major listed insurance companies have successively announced their premium income data for January to November 2024. In terms of life insurance, the premium income of the five listed insurance companies in November increased by a total of 1.7% year-on-year, with the growth rate improving by 2.9 percentage points compared to the previous month. Looking ahead, attention should be paid to the further improvement of the value rate and the progress of preparations for the "New Year's Opening" in 2025. Due to the impact of the switch in the predetermined interest rate, short-term sales are inevitably facing a downturn after a significant release of demand in advance. Combined with the good performance achieved in the first three quarters, various insurance companies have gradually shifted to the preparation work for the "New Year's Opening" in 2025, with the focus moving towards the "reporting and actions" of each insurance company.
Selected announcements | Ping An Insurance's original premium income in the current year is nearly 800 billion yuan; GANFENGLITHIUM's Goulamina spodumene project phase one has officially gone into production.
In the first 11 months, New China Life Insurance accumulated original insurance premium income of 163.1663 billion yuan, a year-on-year increase of 2.2%; Ideal Autos granted a total of 3.94697 million restricted stock units.
Hong Kong Stock Announcement Gold Mining | In the first 11 months, Ping An Insurance's premium income from original insurance contracts totaled approximately 796.3966 billion yuan, a year-on-year increase of 7.86%.
GRANDPHARMA (00512): The Phase II clinical study of the global innovative product STC3141 in China has completed the enrollment of all patients.